文献速递乳腺癌放疗放疗物理与技术

PTCOG国际调查:乳腺癌质子束治疗实践模式与趋势

PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-08-27

粒子治疗协作组(PTCOG)乳腺分委会于2023年6月向全球所有活跃质子束治疗(PBT)中心的乳腺放疗医生发放29题问卷,79份中回收28份(应答率35%)。93%的中心报告用PBT治疗乳腺癌,各洲在分次方案和患者选择方法上存在差异,美国中心经验最多。

要点

  • 93%的应答中心报告使用PBT治疗乳腺癌患者,50%的中心自开业以来已治疗≥100例乳腺癌患者。
  • 46%的中心对区域淋巴结照射采用中度大分割(15–20次),42%采用常规分割(25–30次)。
  • 欧洲中心偏好大分割的比例为88%,高于亚洲的50%和美国的21%(p=0.003)。

核心结论

  • 全球乳腺癌PBT的 utilization、患者选择方法和剂量分次方案存在差异,该调查数据可作为后续调查评估实践模式演变的基准。

研究设计与样本

  • PTCOG乳腺分委会制定经IRB批准的29题调查问卷,于2023年6月发送至全球所有活跃PBT中心的乳腺癌放疗医生,采用描述性统计总结回答,并按洲用Fisher精确检验进行比较。

主要发现

  • 79份问卷中28份提交回答(应答率35%),代表15个美国中心、8个欧洲中心和5个亚洲中心(各洲应答率分别为50%、38%和18%)。
  • 93%的应答中心报告使用PBT治疗乳腺癌患者,13个中心(50%)自开业以来已治疗≥100例乳腺癌患者。
  • 89%的中心具备笔形束扫描技术;46%的中心对区域淋巴结照射采用中度大分割(15–20次),42%采用常规分割(25–30次)。
  • 欧洲中心偏好大分割的比例为88%,亚洲为50%,美国为21%(p=0.003)。
  • 美国中心报告乳腺癌PBT经验最多,71%已治疗≥100例乳腺癌患者,欧洲为38%,亚洲为0(p=0.001)。

关键数值与推荐

  • 常见患者选择方法为医生判断/患者偏好(n=16)和对比计划评估(n=15)。
  • 39%的应答中心将≥75%的乳腺癌PBT患者纳入研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: The indications, techniques, and extent to which proton beam therapy (PBT) is employed for breast cancer are unknown. We seek to determine PBT utilization for breast cancer. MATERIALS/METHODS: The Particle Therapy Co-Operative Group (PTCOG) Breast Subcommittee developed an IRB-approved 29-question survey and sent it to breast cancer radiation oncologists at all active PBT centers worldwide in June 2023. Descriptive statistics were used to summarize responses, and comparisons by continent were performed using Fisher's exact tests. RESULTS: Of 79 surveys distributed, 28 recipients submitted responses (35 % response rate) representing fifteen U.S., 8 European, and 5 Asian centers (continent response rate 50 %, 38 %, and 18 %, respectively). Overall, 93 % reported treating breast cancer patients with PBT; 13 (50 %) have treated ≥100 breast cancer patients at their center since opening. Most (89 %) have pencil beam scanning technology. Nearly half (46 %) use moderate hypofractionation (15-20 fractions) for regional nodal irradiation and 42 % conventional fractionation (25-30 fractions). More European centers prefer hypofractionation (88 %) vs. Asian (50 %) and U.S. (21 %) centers (p = 0.003). Common patient selection methods were practitioner determination/patient preference (n = 16) and comparative plan evaluation (n = 15). U.S. centers reported the most experience with breast PBT, with 71 % having treated ≥100 breast cancer patients vs. 38 % in Europe and none in Asia (p = 0.001). Of respondent centers, 39 % enrolled ≥75 % of breast PBT patients on a research study. CONCLUSION: Utilization, patient selection methods, and dose-fractionation approaches for breast cancer PBT vary worldwide. These survey data serve as a benchmark from which successor surveys can provide insight on practice pattern evolution.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Choi JI, Hardy-Abeloos C, Lozano A, et al. PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer. Clin Transl Radiat Oncol. 2024. PMID: 39280125. doi:10.1016/j.ctro.2024.100847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。